Richard Gaynor, M.D., has been appointed president of research and development at Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer. Dr. Gaynor succeeds interim chief scientific officer Robert Tepper, M.D., a partner at Third Rock Ventures, who is continuing as a member of the company’s board.   Dr. Gaynor recently retired from Eli Lilly’s oncology division, where he served as senior vice president of global prod...